EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Polymeric nanoparticle-mediated GBA1 gene therapy is neuroprotective in a preclinical model of Parkinson’s disease

Mohit Kwatra, Gijung Kwak, Haolin Li, Jung Soo Suk, Han Seok Ko

Drug Delivery and Translational Research · 2026-03 · 16 (3) · 894-910

DOI: 10.1007/s13346-025-01944-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Delivery and Translational Research, online erschienen am 20.08.2025. Verfasst von Mohit Kwatra und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Cell Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA. Hauptthemen laut MEDLINE: Glucosylceramidase, Genetic Therapy, Nanoparticles, Parkinson Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NEI NIH HHS, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson’s disease (PD) is a debilitating neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra (SN). It manifests with hallmark motor symptoms such as tremors, rigidity, and bradykinesia, as well as severe non-motor complications. Current therapies provide symptomatic relief but fail to halt or reverse neurodegeneration, emphasizing that a disease-modifying treatment option is sorely needed. Mutations in glucocerebrosidase 1 (GBA1) gene encoding GCase or mutation-free reduction of GCase activity disrupt lysosomal function and drive α-synuclein (α-syn) accumulation, thereby leading to neuronal and motor function loss. To this end, restoring GCase activity by GBA1 gene therapy would potentially benefit a broad PD population with or without the genetic risk by intervening with the natural trajectory of the disease. In this study, we implemented localized GBA1 gene therapy by intracranial convection-enhanced delivery of plasmid DNA comprising human GBA1 gene carried by engineered polymeric nanoparticles capable of mediating widespread neuronal transgene expression. In an α-syn preformed fibril (PFF)-induced mouse model of PD, our therapeutic strategy mediated robust human GBA1 transgene expression in the SN to significantly reduce α-syn aggregation/accumulation, preserve tyrosine hydroxylase-positive dopaminergic neurons, and mitigate neuroinflammation. Remarkably, motor deficits were markedly improved, as demonstrated by grip strength, pole, and open field tests. These findings underscore the transformative potential of our nanoparticle-based GBA1 gene therapy in addressing the limitations of current standard-of-care treatments. We expect that our therapeutic strategy, upon clinical development and translation, may contribute to shifting the therapeutic paradigm from the current symptomatic management toward disease modification to ultimately provide PD patients with a curative therapeutic option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosylceramidaseGenetic TherapyNanoparticlesParkinson DiseaseAnimalsHumansDisease Models, Animalalpha-SynucleinMiceGene Therapy AgentsPolymersMaleMice, Inbred C57BL

Stichwörter der Autor:innen

Convection-enhanced deliveryGCaseGlucocerebrosidase 1Intracranial gene therapyNeuroinflammationNeuroprotectionPolymeric nanoparticleΑlpha-synuclein

Substanzen

Glucosylceramidasealpha-SynucleinGBA protein, humanPolymers

Autor:innen und Institutionen

  • Institute for Cell Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.
  • Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.
  • Department of Ophthalmology, College of Medicine, Medical University of South Carolina (MUSC), Charleston, SC, 29425, USA.
  • Department of Neurosurgery, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA.
  • Medicine Institute for Neuroscience Discovery (UM-MIND), School of Medicine, University of Maryland, Baltimore, MD, 21201, USA.
  • Department of Chemical and Biomolecular Engineering, School of Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.

Förderung

  • NINDS NIH HHS
  • NEI NIH HHS
  • National Institute of Neurological Disorders and Stroke
  • National Eye Institute

Zitieren

APA

Kwatra, M., Kwak, G., Li, H., Suk, J. S., & Ko, H. S. (2026). Polymeric nanoparticle-mediated GBA1 gene therapy is neuroprotective in a preclinical model of Parkinson’s disease. Drug Delivery and Translational Research, 16(3), 894-910. https://doi.org/10.1007/s13346-025-01944-3

Vancouver

Kwatra M, Kwak G, Li H, Suk JS, Ko HS. Polymeric nanoparticle-mediated GBA1 gene therapy is neuroprotective in a preclinical model of Parkinson’s disease. Drug Delivery and Translational Research. 2026;16(3):894-910. doi:10.1007/s13346-025-01944-3

BibTeX
@article{Kwatra2026,
  author = {Kwatra, Mohit and Kwak, Gijung and Li, Haolin and Suk, Jung Soo and Ko, Han Seok},
  title = {Polymeric nanoparticle-mediated GBA1 gene therapy is neuroprotective in a preclinical model of Parkinson’s disease},
  journal = {Drug Delivery and Translational Research},
  year = {2026},
  volume = {16},
  number = {3},
  pages = {894--910},
  doi = {10.1007/s13346-025-01944-3}
}
Kostenlos starten →